Ashburn, Virginia — March 9, 2026
Clinical-stage specialty biopharmaceutical company Quoin Pharmaceuticals Ltd. continues to advance the development of QRX003, its investigational topical therapy designed to treat Netherton Syndrome, a rare and potentially life-threatening genetic skin disorder. The company reported progress in regulatory and clinical development activities for the therapy, reinforcing its commitment to addressing significant unmet medical needs in rare dermatological diseases. QRX003 represents a targeted therapeutic approach designed to correct the underlying skin barrier dysfunction associated with the disease, offering hope for patients who currently lack approved treatment options.
Quoin Pharmaceuticals focuses on developing therapies for rare and orphan diseases, with several pipeline candidates targeting dermatological conditions and immune-related disorders. The advancement of QRX003 highlights the company’s broader strategy of delivering innovative treatments that could significantly improve quality of life for individuals affected by rare medical conditions.
Investigational Therapy Targets Rare Genetic Skin Disorder
Netherton Syndrome is a rare inherited disorder characterized by severe skin inflammation, compromised skin barrier function, and increased susceptibility to infections. Patients often experience chronic redness, scaling, and itching, along with systemic complications that can significantly impact long-term health and quality of life. Because the condition affects a very small patient population, treatment options remain limited and are largely focused on symptom management rather than addressing the underlying biological mechanisms of the disease.
Quoin’s QRX003 topical lotion (4%) has been developed to target the molecular pathways responsible for the impaired skin barrier seen in Netherton Syndrome. By strengthening the skin barrier and reducing inflammation, the therapy aims to restore skin function and reduce the severe symptoms associated with the disorder. The investigational drug is currently being evaluated in late-stage pivotal clinical trials, which are designed to assess its safety and effectiveness in patients with the condition.
Advertisement
Enrollment in these pivotal studies is expected to conclude in 2026, with top-line clinical results anticipated later the same year. If the trials demonstrate positive outcomes, the company plans to pursue regulatory submissions that could ultimately lead to the first approved treatment specifically designed for Netherton Syndrome.
Regulatory Milestones Support Rare Disease Drug Development
The development of QRX003 has already received important regulatory recognition aimed at accelerating treatments for rare diseases. The therapy previously received Orphan Drug Designation from the U.S. Food and Drug Administration, a status granted to investigational medicines intended to treat conditions affecting fewer than 200,000 patients in the United States. This designation provides significant incentives for drug developers, including tax credits for clinical research, reduced regulatory fees, and the potential for seven years of market exclusivity if the therapy receives approval.
The therapy has also received similar recognition from regulatory authorities in other regions, highlighting the medical community’s interest in developing treatments for this rare genetic disorder. These regulatory incentives are designed to encourage pharmaceutical innovation in areas where traditional market forces may not support the costly research and development required to bring new therapies to patients.
By leveraging these regulatory pathways, Quoin Pharmaceuticals aims to accelerate the development timeline for QRX003 and expand global access to treatment options for individuals living with Netherton Syndrome.
Expanding Innovation in Rare and Orphan Disease Therapies
Beyond QRX003, Quoin Pharmaceuticals maintains a broader research pipeline focused on therapies targeting rare dermatological and inflammatory diseases. The company’s scientific strategy emphasizes developing treatments that address the root biological causes of disease rather than simply managing symptoms.
The company is exploring additional therapeutic opportunities in conditions such as Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Microcystic Lymphatic Malformations, and other rare disorders where current treatment options remain limited. By focusing on these underserved medical areas, Quoin seeks to provide meaningful therapeutic advancements for patients who often face long diagnostic journeys and limited access to effective care.
The continued advancement of QRX003 underscores the growing importance of precision medicine approaches in rare disease treatment, where therapies are designed to target specific molecular mechanisms responsible for disease progression. If successful, the therapy could represent a significant breakthrough for patients affected by Netherton Syndrome and further strengthen the role of innovative biotechnology companies in developing treatments for rare conditions.
As clinical research progresses and regulatory discussions continue, Quoin Pharmaceuticals remains focused on bringing forward transformative therapies for patients living with rare genetic diseases, reinforcing the importance of targeted research, regulatory support, and sustained investment in orphan drug development.
z
Source: Quoin Pharmaceuticals press release
